Intercept Pharmaceuticals Inc  

(Public, NASDAQ:ICPT)   Watch this stock  
Find more results for ICPT
+0.13 (0.07%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 180.10 - 184.96
52 week 128.50 - 314.88
Open 182.63
Vol / Avg. 303,282.00/598,279.00
Mkt cap 4.47B
P/E     -
Div/yield     -
EPS -7.50
Shares 24.33M
Beta -4.20
Inst. own 77%
Dec 1, 2015
Intercept Pharmaceuticals Inc Analyst/Investor Event - 9:00AM EST - Add to calendar
Nov 24, 2015
Intercept Pharmaceuticals Inc Annual Shareholders Meeting
Nov 16, 2015
Intercept Pharmaceuticals Inc Investor Event
Nov 9, 2015
Q3 2015 Intercept Pharmaceuticals Inc Earnings Release
Nov 9, 2015
Q3 2015 Intercept Pharmaceuticals Inc Earnings Call
Oct 28, 2015
Intercept Pharmaceuticals Inc Announces Phase 2 Trial of OCA in NASH Patients in Japan Conference Call
Sep 16, 2015
Intercept Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 10, 2015
Intercept Pharmaceuticals Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -11437.30% -16262.21%
Operating margin -11636.85% -6497.98%
EBITD margin - -6472.56%
Return on average assets -27.76% -140.05%
Return on average equity -29.15% -180.80%
Employees 136 -
CDP Score - -


450 W 15th St Ste 505
NEW YORK, NY 10011-7082
United States - Map
+1-646-7471000 (Phone)
+1-646-7471001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Officers and directors

Jonathan T. Silverstein J.D. Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Mark Pruzanski M.D. President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Barbara G. Duncan Chief Financial Officer, Treasurer, Secretary
Age: 50
Bio & Compensation  - Reuters
David M. Shapiro M.D. Chief Medical Officer, Executive Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Luciano Adorini M.D. Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
Lisa Bright chief commercial and corporate affairs officer
Age: 47
Bio & Compensation  - Reuters
Rachel L. McMinn Ph.D. Chief Strategy Officer
Age: 42
Bio & Compensation  - Reuters
Srinivas Akkaraju M.D., Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Luca Benatti Ph.D Independent Director
Age: 54
Bio & Compensation  - Reuters
Paolo Fundaro Independent Director
Age: 41
Bio & Compensation  - Reuters